References
Every citation used across the reference, searchable and linked to its primary source. Inclusion is not endorsement.
- 1Body Composition, Hepatic Fat, Metabolic, and Safety Outcomes of Tesamorelin: A Meta-Analysis of Randomized Controlled Trials
- 2Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- 3Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
- 4Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- 5Effects of retatrutide on body composition in people with type 2 diabetes: a phase 2 substudy
- 6Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
- 7Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
- 8Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review
- 9Intranasal Kisspeptin Administration Rapidly Stimulates Gonadotropin Release in Humans
- 10Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE)
- 11Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
- 12The Efficacy and Safety of Thymosin Alpha 1 for Sepsis (TESTS): Multicentre, Double-Blinded, Randomised, Placebo-Controlled, Phase 3 Trial
- 13Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
- 14Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-Year Extension)
- 15TRIUMPH registrational clinical trials: Rationale and design
- 16A Randomized Placebo-Controlled Trial of Nicotinamide Riboside in Older Adults with Mild Cognitive Impairment
- 17A Synthetic ERR Agonist Alleviates Metabolic Syndrome
- 18
- 19Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects
- 20Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
- 21Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
- 22Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)
- 23Efficacy of Oral NMN Supplementation on Glucose and Lipid Metabolism: A Systematic Review with Meta-Analysis of RCTs
- 24Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice
- 25Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- 26Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
- 27Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
- 28Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
- 29Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
- 30Tripeptides GHK and GHK-Cu-modified silver nanoparticles for enhanced antibacterial and wound healing activities
- 31Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- 32Alzheimer's Mouse Model Study
- 33Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets
- 34
- 35Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis
- 36Certain Bulk Drug Substances for Compounding — BPC-157 (Category 2)FDA labelno link recorded
- 37Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
- 38Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- 39Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
- 40Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
- 41Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
- 42Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
- 43Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
- 44Stroke Recovery & Cognitive Function Review
- 45Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
- 46Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application
- 47Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
- 48Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- 490.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
- 50Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
- 51Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients
- 52MOTS-c Increases in Skeletal Muscle Following Long-Term Physical Activity and Improves Acute Exercise Performance After a Single Dose
- 53Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)
- 54The Mitochondrial-Derived Peptide MOTS-c Relieves Hyperglycemia and Insulin Resistance in Gestational Diabetes Mellitus
- 55Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
- 56Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
- 57A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
- 58AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
- 59Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats After Focal Stroke
- 60Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies
- 61Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- 62MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis
- 63NAD+ Metabolism and Its Roles in Cellular Processes During Ageing
- 64Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women
- 65Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
- 66TAZPOWER: Phase 2/3 Randomized Clinical Trial of Elamipretide in Barth Syndrome
- 67The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal Women
- 68Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
- 69A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
- 70AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
- 71
- 72BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection
- 73Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank
- 74Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy
- 75Efficacy and Safety of Cerebrolysin in Neurorecovery After Moderate-Severe Traumatic Brain Injury: Results from the CAPTAIN II Trial
- 76
- 77Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
- 78The single-chain relaxin mimetic, B7-33, maintains anti-fibrotic activity in liver and kidney fibrosis models
- 79Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
- 80Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)
- 81Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial
- 82Human Chorionic Gonadotropin Monotherapy for the Treatment of Hypogonadal Symptoms in Men with Total Testosterone >300 ng/dL
- 83Improving Mitochondrial Function with SS-31 Reverses Age-Related Redox Stress and Improves Exercise Tolerance in Aged Mice
- 84Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)
- 85Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
- 86Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults
- 87Effects of Semax on the Default Mode Network of the Brain (Parent Compound)
- 88Efficacy and Safety of Human Chorionic Gonadotropin for Treatment of Cryptorchidism: A Meta-Analysis of Randomised Controlled Trials
- 89Fertility Induction in Hypogonadotropic Hypogonadal Men
- 90Parkinson's Disease Clinical Study
- 91Randomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy (MMPOWER)
- 92Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
- 93Safety and Efficacy of Cerebrolysin in Early Post-Stroke Recovery: A Meta-Analysis of Nine Randomized Clinical Trials
- 94Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
- 95The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound)
- 96The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
- 97The relaxin receptor as a therapeutic target -- perspectives from evolution and drug targeting
- 98A phase 2 trial of ACE-031, a soluble activin receptor type IIB, in boys with Duchenne muscular dystrophy
- 99
- 100B7-33 replicates the vasoprotective effects of relaxin in mouse models of cardiovascular disease
- 101Cerebrolysin for Functional Recovery in Patients with Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
- 102Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
- 103Novel Mitochondria-Targeting Peptide in Heart Failure Treatment (EMBRACE)
- 104Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
- 105The role of relaxin and its receptor (RXFP1) in the pathogenesis and treatment of fibrotic diseases
- 106Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
- 107A single-chain peptide derived from the relaxin B-chain selectively activates RXFP1
- 108Cardiovascular Risk in Growth Hormone Deficiency: Beneficial Effects of Growth Hormone Replacement Therapy
- 109Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV
- 110Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
- 111Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
- 112The Effectiveness of hCG and LHRH in Boys with Cryptorchidism: A Meta-Analysis of Randomized Controlled Trials
- 113ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
- 114Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials
- 115Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
- 116Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF Therapy
- 117GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
- 118Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals
- 119The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's Diseases
- 120The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
- 121Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial
- 122A Comparison of the Anxiolytic Effect and Tolerability of Selank and Phenazepam in the Treatment of Anxiety Disorders
- 123Efficacy and Safety of Growth Hormone Treatment in Adults with Growth Hormone Deficiency: A Systematic Review of Studies on Morbidity
- 124IGF-1 Homeostasis Regulation Study
- 125NAD+ and Sirtuins in Aging and Disease
- 126Pharmacokinetic, pharmacodynamic, and safety results from a first-in-human study of ACE-031, a novel activin receptor type IIB/Fc fusion protein
- 127Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
- 128The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound)
- 129The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System
- 130A soluble activin receptor type IIB (ACE-031) increases lean body mass and muscle strength in healthy postmenopausal women
- 131Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents
- 132FGL, a Neural Cell Adhesion Molecule-Derived Peptide, Promotes Recovery in a Rat Model of Stroke
- 133Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock
- 134The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects: A Randomized, Placebo-Controlled Study
- 135DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's Disease
- 136Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with MCI and Healthy Older Adults
- 137Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1
- 138The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health
- 139The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients
- 140Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications
- 141Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's Disease
- 142The promoting effect of pentadecapeptide BPC 157 on tendon healing
- 143DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
- 144Effects of Tesamorelin in HIV-Infected Patients with Abdominal Fat Accumulation: Randomized Placebo-Controlled Trial with Safety Extension (CTR-1011)
- 145Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse
- 146Experimental Optimization of Learning and Memory Processes by Selank
- 147Human skin penetration of a copper tripeptide in vitro as a function of skin layer
- 148A Peptide Agonist of the Neural Cell Adhesion Molecule NCAM, FGL, Enhances Synaptogenesis and Memory in Rats
- 149Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects
- 150Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
- 151A Small Nonerythropoietic Helix B Surface Peptide Based Upon Erythropoietin Structure Is Cardioprotective Against Ischemic Myocardial Damage
- 152Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
- 153Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia
- 154Enhancement of Long-Term Potentiation and Memory by the NCAM-Derived Peptide FGL
- 155Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo
- 156Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease
- 157PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
- 158Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study
- 159Development of thymosin beta4 for treatment of patients with ischemic heart disease
- 160Metabolic effects of a growth hormone-releasing factor in patients with HIV
- 161The effect of tripeptide-copper complex on human hair growth in vitro
- 162Thymosin Alpha 1: A Historical Overview
- 163Unmasking of Central Hypothyroidism Following Growth Hormone Replacement in Adult Hypopituitary Patients
- 164Discovery that a Melanocortin Regulates Sexual Functions in Male and Female Humans
- 165Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157
- 166Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
- 167Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
- 168Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
- 169Semax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound)
- 170Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
- 171Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts
- 172Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
- 173Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression
- 174Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile Dysfunction
- 175Glutathione metabolism and its implications for health
- 176MT-I Photoprotection Study
- 177Myostatin inhibition in health and disease
- 178The FGL Peptide Derived from NCAM Acts as a Neurotrophic Factor and Promotes Neurite Outgrowth and Survival of Neurons
- 179Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone Peptides
- 180Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice
- 181Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
- 182Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
- 183Peptides of pineal gland and thymus prolong human life
- 184A Synthetic Hexapeptide (Argireline) with Antiwrinkle Activity
- 185Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptors
- 186Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
- 187Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
- 188Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
- 189Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys
- 190The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
- 191The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
- 192Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
- 193Increased Eumelanin Expression and Tanning Is Induced by a Superpotent Melanotropin [Nle4-D-Phe7]-alpha-MSH in Humans
- 194Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies with Melanotan II
- 195Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
- 196Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
- 197Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
- 198Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
- 199Thymosin Beta-4 Accelerates Wound Healing
- 200Ipamorelin, the first selective growth hormone secretagogue
- 201MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
- 202Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
- 203A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound)
- 204Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
- 205Melanocortin Receptor Binding Study
- 206Natural and synthetic thymic peptides as therapeutics for immune dysfunction
- 207Pharmacokinetics Injectable MT-I
- 208Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
- 209Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men
- 210Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study
- 211Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
- 212Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects
- 213Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growth
- 214Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind Study
- 215Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
- 216Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia
- 217Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
- 218The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature
- 219The isolation and characterization of a naturally occurring truncated form of IGF-I in human brain
- 220DSIP in the Treatment of Withdrawal Syndromes from Alcohol and Opiates
- 221Successful Treatment of Withdrawal Symptoms with Delta Sleep-Inducing Peptide
- 222Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes: A Clinical Pilot Study
- 223Acute and Delayed Effects of DSIP (Delta Sleep-Inducing Peptide) on Human Sleep Behavior
The index grows as monographs are written, so it currently covers a small part of the corpus. Each identifier is checked to resolve to the paper it claims — two that did not have already been removed.